











Prior Authorization Request Administrative Information

Member Information					
Last name	First name		МІ		
Member ID	Date of birth				
	X" or Intersex				
Current gender Female Male Transge	ender male 🔲 Tra	nsgender female Othe	-		
Place of residence Home Nursing facility	Other				
Race/ethnicity Preferred spoken la	anguage	Preferred written lang	uage		
MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).					
Plan Contact Information					
Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to the Plan's contact information below.					
MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan					
☐ MassHealth Drug Utilization Review Prog	gram				
Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318				
MassHealth Managed Care Organization	n (MCO) and Acco	untable Care Partnershi	p Plans (ACPP)		
☐ Fallon Health					
Online Prior Authorization: go.covermymeds.com/OptumRx					
Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum					
Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033					
☐ Health New England					
Online Prior Authorization: go.covermymeds.com/OptumRx					
Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545					
☐ Mass General Brigham Health Plan					
Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx					
Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org					
Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555					
☐ Tufts Health Plan					
Online Prior Authorization: point32health.promptpa.com					
Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985					
□ WellSense Health Plan					
Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations					
Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822					

Multiple Myeloma Agents Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist**.

Medication information	
Medication requested	
☐ Blenrep (belantamab mafodotin-blmf)	☐ Kyprolis (carfilzomib) MB
☐ Darzalex (daratumumab) ^{MB}	☐ Ninlaro (ixazomib)
☐ Darzalex Faspro (daratumumab-	☐ Pomalyst (pomalidomide)
hyaluronidase-fihj) ^{MB}	☐ Sarclisa (isatuximab-irfc) MB
☐ Empliciti (elotuzumab) ^{MB}	☐ Xpovio (selinexor)
inpatient hospital setting. MassHealth does not listed, prior authorization does not apply through 130 CMR 433.408 for prior authorization requabove, this drug may be an exception to the	are professional who administers the drug or in an outpatient or of pay for this drug to be dispensed through the retail pharmacy. If the hospital outpatient and inpatient settings. Please refer to uirements for other health care professionals. Notwithstanding the unified pharmacy policy; please refer to respective MassHealth and Managed Care Organizations (MCOs) for prior authorization
Dose, frequency, and duration of medicati	on requested
Height	Weight
Please indicate prescriber specialty: Will the requested agent be used as monother of the second s	••
<u> </u>	acy Prescriber in-office Hospital outpatient r professionally administered medications at end of form.
Drug NDC (if known) or service code	
Indication (Check all that apply or include IC Multiple myeloma Other Oncologic Indications Diffuse large B-cell lymphoma (DLBCI	
☐ Kaposi sarcoma	
Acquired Immunodeficiency SyndrNegative for Human Immunodefici	ome (AIDS) and failed highly active antiretroviral therapy ency Virus (HIV)

PA-84 (Rev. 04/24) over

Please describe the stage and severity of disease.					
Is the cancer metastatic? Yes No					
Has the member had persistent or recurring disease following surgery ar	nd/or radiation therapy? Yes No				
Is the member a candidate for surgery and/or radiation?					
☐ Yes ☐ No. Please describe.					
Section I. Please complete for all requests.					
Please list any other prior trials. Please list the drug names, dates/duration	on of use and outcomes below.*				
Drug name Dates/o	luration of use				
Did the member experience any of the following? Adverse reaction					
Briefly describe details of adverse reaction, inadequate response, or other	er.				
3	luration of use				
Did the member experience any of the following? Adverse reaction	•				
Briefly describe details of adverse reaction, inadequate response, or other	er.				
Drug name Dates/d	luration of use				
Did the member experience any of the following? Adverse reaction	•				
Briefly describe details of adverse reaction, inadequate response, or other	er.				
5	luration of use				
Did the member experience any of the following? Adverse reaction	- · · · —				
Briefly describe details of adverse reaction, inadequate response, or other	er. 				
Drug name Dates/o	luration of use				
Did the member experience any of the following? Adverse reaction					
Briefly describe details of adverse reaction, inadequate response, or other	er.				
* Please attach a letter documenting additional trials as necessary.					
Section II Disease complete for Dispuser and Vaccin for many	th a report required to				
Section II. Please complete for Blenrep, and Xpovio for mono 1. Has the member received at least four prior chemotherapy regimens					
2. Is the member's disease refractory to at least one proteasome inhibit	· —				
proteasome inhibitors (for Xpovio requests), or does the member have	,				
inhibitors? Yes. Complete Section I. No					
3. Is the member's disease refractory to at least one immunomodulatory agent (for Blenrep requests) or two					
immunomodulatory agents (for Xpovio requests), or does the member immunomodulatory agents? Yes. Complete Section I. No	er nave a contraindication to				
4. Is the member's disease refractory to at least one anti-CD38 monocl	onal antibody, or does the member				
have a contraindication to anti-CD38 monoclonal antibodies? Yes. Complete Section I. No					

	Please complete for requests for agents with a preferred alternative. cribe clinical rationale for use of the requested agent instead of the preferred alternative.
	Please complete for requests for quantities above quantity limits. cribe the clinical rationale for exceeding the quantity limit, including a detailed treatment plan.
Section V.	Please include any other pertinent information (if needed).
 Is the alt reaction 	Please complete and provide documentation for exceptions to Step Therapy. ernative drug required under the step therapy protocol contraindicated, or will likely cause an adverse in, or physical or mental harm to the member? Yes No briefly describe details of contraindication, adverse reaction, or harm.
clinical c ☐ Ye	ernative drug required under the step therapy protocol expected to be ineffective based on the known haracteristics of the member and the known characteristics of the alternative drug regimen? S No briefly describe details of known clinical characteristics of member and alternative drug regimen.
alternativ drug was \ Ye If yes, Drug r Did the	member previously tried the alternative drug required under the step therapy protocol, or another we drug in the same pharmacologic class or with the same mechanism of action, and such alternative discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event? Solvential No please provide details for the previous trial. Dates/duration of use Describe details of adverse reaction or inadequate response.

4.	Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in or physical or mental harm to the member?				
	☐ Yes. Please provide details. ☐ No				
Ρl	ease continue to next page and complete Prescriber and Provider Information section.				

Prior Authorization Request Prescriber and Provider Information

Prescriber Information		
Last name*	First name*	MI
NPI*	Individual MH Provide	er ID
DEA No.	Office Contact Name	
Address	City	State Zip
Email address		
Telephone No.*	Fax No.*	
* Required		
Please also complete for professionally	administered medication	ns, if applicable.
Start date	End date	_
Servicing prescriber/facility name		☐ Same as prescribing provider
Servicing provider/facility address		
Servicing provider NPI/tax ID No.		
Name of billing provider		
Billing provider NPI No.		
Is this a request for recertification? Yes] No	
CPT code No. of visits	J code	No. of units
Prescribing provider's attestation, signal certify under the pains and penalties of perjoinformation section of this form. Any attached I certify that the medical necessity information complete, to the best of my knowledge. I under prosecution for any falsification, omission, or	ury that I am the prescribing I statement on my letterhead (per 130 CMR 450.204) on erstand that I may be subject concealment of any material	has been reviewed and signed by me. this form is true, accurate, and to civil penalties or criminal I fact contained herein.
Prescribing provider's signature		_
Printed name of prescribing provider (The form can either be signed by hand and		

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)